Clinical trialsCompany release

Eton licenses Baylor IGF-1 patents and files IND for mecasermin in refractory spasms

🇺🇸 Eton Pharmaceuticals, Inc. (ETON) · Mon 02 Nov 2026

Eton Pharmaceuticals has launched ET-900 to test mecasermin, the active ingredient in INCRELEX, in infantile and epileptic spasms, with first dosing targeted for the first quarter of 2027.

Eton Pharmaceuticals announced on 2 November 2026 that it has signed a licence with Baylor College of Medicine and started a new programme, ET-900. The programme will evaluate mecasermin, the active ingredient in INCRELEX, for infantile and epileptic spasms.

A research investigational new drug (IND) application has been submitted to the US Food and Drug Administration. It covers a Phase 2 study sponsored by the University of Chicago, which is planned to enrol up to 20 children with refractory spasms.

Eton is targeting first dosing in the first quarter of 2027. Mecasermin is not approved for this use, so the planned work is investigational.

The announcement does not give further detail on the licence terms, the study design or the endpoints.

What it means for your team

  • Mecasermin use in refractory epileptic spasms is investigational only; it is not an approved indication.
  • The Phase 2 study is small, with up to 20 children, and sponsored by an academic centre under a research IND. Any safety data would come from a limited paediatric population.
  • Teams tracking paediatric epilepsy or rare-disease pipelines should watch for the study start in Q1 2027.

Company's press release (SEC filing): Eton Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Eton Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →